The Japanese yen experienced a notable appreciation, reaching its highest level in three months against the US dollar, following a coordinated currency intervention by the US and Japanese governments [2]. This joint action, confirmed by both nations, was executed late last week with the explicit aim of supporting the Japanese currency [2].
What Happened
- The yen strengthened to ¥155 to the US dollar on Monday, marking its highest level since early May [2].
- This appreciation followed a rare joint currency intervention by the US and Japanese governments, confirmed by both parties [2].
- The intervention was carried out late last week with the explicit aim of supporting the Japanese currency [2].
- British manufacturing activity grew for a ninth consecutive month in July, though at its slowest pace in four months, with the S&P Global Purchasing Managers’ Index falling to 51.9 from 52.5 in June [1].
- Despite the slowdown, July saw accelerated growth rates in output, new orders, and new export business for the UK manufacturing sector, with production increasing at its fastest rate in almost two years [1].
- EY has warned that the UK economy faces a recession if the Strait of Hormuz remains closed [1].
- AstraZeneca is reportedly in discussions to acquire its US rival Bristol Myers Squibb in a deal valued at nearly $400 billion, which would create the world’s fourth-largest drugmaker [3].
- US President Donald Trump has introduced new tariffs, citing the pretext of stopping forced labor, which critics argue is a ruse to secure a larger share of global trade for the US [4].
Why It Matters
The joint US-Japan currency intervention underscores a significant shift in international economic policy coordination, particularly given the rarity of such actions [2]. It signals a shared concern over currency volatility and its potential impact on global trade and financial stability. The yen's strengthening could alleviate inflationary pressures in Japan and stabilize import costs, though it may also affect export competitiveness.
The UK manufacturing data presents a mixed economic picture [1]. While nine consecutive months of growth indicate resilience, the decelerating pace of the PMI suggests underlying headwinds or a moderation in expansion. The acceleration in output and new orders, however, provides a counterpoint, indicating specific areas of strength within the sector that could support broader economic activity.
The warning from EY regarding a potential UK recession if the Strait of Hormuz remains closed highlights a critical vulnerability to geopolitical events and supply chain disruptions [1]. Such a closure would likely impact energy prices and trade routes, posing a significant risk to the UK's economic stability and growth trajectory. This forecast adds a layer of caution to the otherwise mixed manufacturing data.
The proposed AstraZeneca-Bristol Myers Squibb merger, if realized, would represent one of the largest pharmaceutical deals in history, creating a near-$400 billion entity [3]. Such a consolidation could reshape the global pharmaceutical landscape, impacting research and development, market competition, and drug pricing. For the UK, it would involve its second-biggest listed company, potentially affecting its corporate sector and investment profile.
President Trump's new tariffs, framed under the guise of combating forced labor, introduce further uncertainty into global trade relations [4]. While the stated aim addresses a legitimate concern, the timing and nature of these tariffs, which closely track previous protectionist measures, suggest a broader strategy to reallocate global trade shares. This could provoke retaliatory measures and disrupt supply chains, impacting international commerce and economic growth.
Signals To Watch (Next 72 Hours)
- Further statements or actions from the US Treasury and Bank of Japan regarding currency market stability [2].
- The yen's performance against major currencies in the coming days, particularly its ability to sustain levels around ¥155 to the US dollar [2].
- Official confirmation or denial of the AstraZeneca-Bristol Myers Squibb merger discussions and any subsequent regulatory filings [3].
- Market reactions to the potential pharmaceutical merger, including stock movements of both companies and their competitors [3].
- Responses from international trading partners and organizations to President Trump's new tariffs and their stated pretext [4].
- Any new economic data from the UK that could provide further clarity on the manufacturing sector's trajectory and broader economic health [1].
- Statements from EY or other economic forecasters regarding the UK's economic outlook, especially concerning potential recession risks related to geopolitical events [1].
These developments underscore a period of significant economic and corporate activity with potential global ramifications.
Sources
- UK economy faces recession if strait of Hormuz remains closed, EY warns - business live — Guardian Business · Aug 03, 2026
- Yen hits three-month high after Trump helps prop up currency — Guardian Business · Aug 03, 2026
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger — Guardian Business · Aug 03, 2026
- Trump’s hypocritical new tariffs are a chance for the world to fight back | Joseph Stiglitz — Guardian Business · Aug 03, 2026
